lazertinib,amivantamab
yuhan corp,Janssen,oscotec,genmab
['sclc', 'lazertinib', 'nsclc']
 if pt has sclc converted from nsclc (prog on mariposa amivantamab/lazertinib arm, is sclc treatment 1l since new morphology or 2l since mariposa. &amp;who are experts in this conversion/options?
not an encouraging data point